Business
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
- 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. - Dose response was
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"- 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels.\n - Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level.\n - Tumor proportion score (TPS) was selected as an appropriate scoring algorithm for identifying an enriched target patient population based on FolRa expression levels.\n - An ORR of 40% was observed for patients with TPS >25%, which, based on our patient data, represents about 70% of the advanced ovarian cancer patient population.\n - Emerging safety profile was generally consistent with prior STRO-002 data, with no new safety signals observed, including the absence of keratopathy.\n - Co-principal investigator, Dr. Naumann, and Sutro management will present data at a STRO-002 virtual event at 2 pm PT/5 pm ET today.\n\n\nSOUTH SAN FRANCISCO, Calif., Jan. 5, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. (\"Sutro\" or the \"Company\") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today provided a clinical update from the Company's ongoing, fully enrolled, dose-expansion Phase 1 study of STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC), for patients with advanced ovarian cancer. Discussion of these data will be held at a STRO-002 Virtual Event at 2 pm PT/5 pm ET today. \n\"These interim data in the dose-expansion cohort showing deep responders in ovarian cancer patients treated with STRO-002 are compelling,\" said Dr. R. Wendel Naumann, Professor & Director of Gynecologic Oncology Research, Associate Medical Director of Clinical Trials at Levine Cancer Institute, and an investigator on the STRO-002 study. \"Patients entered the study with progressive disease and were a heavily pre-treated population and had experienced up to three lines of prior treatment. The interim data show that STRO-002 could potentially improve the lives of an underserved ovarian cancer patient population.\" \nThe dose-expansion cohort for ovarian cancer enrolled 44 patients who had experienced up to three prior lines of therapy. As of the interim data cutoff date of Nov. 8, 2021, 43 patients had been randomized i...